F
etal bovine serum (FBS) remains the most widely used serum supplement for culturing mammalian cells. With the advent of using culturederived mammalian cells for therapeutic applications, there is an active pursuit to eliminate xenogeneic supplements in culture medium. Several reasons for this change include avoiding risks associated with transmitting infectious bovine agents (i.e., parvovirus and prions) and exposure to residual xenoproteins, which potentially could cause immune reactions in patients. Other motivating factors for replacing FBS include batch-to-batch variations associated with different FBS lots and the rising ethical concerns surrounding the inhumane practices for collecting bovine fetal blood that is used to manufacture FBS. 1 Strategies under investigation to replace FBS in mammalian cell cultures include the development of a chemically defined culture medium that is free of xenogeneic components or the use of a human serum source as a protein supplement in a culture basal medium. Progress with developing chemically defined medium is being made, 2 but a drawback of serum-free media is that they typically have suboptimal performance 3 and fail to support the attachment of cells to a surface or substrate unless the culture plates are precoated with factors that facilitate cellular attachment (i.e., fibronectin). 4 Human protein sources as replacements for FBS include autologous adult serum, pooled AB serum, umbilical cord blood serum, and platelet lysate (PL), [5] [6] [7] all of which have been used intermittently in the past to promote mammalian cell cultures. [8] [9] [10] [11] [12] Of these strategies, PL is emerging as one of the most viable alternatives to FBS. Mesenchymal stromal cells (MSCs), when cultured with PL, tend to have greater proliferation responses and better cloning efficiencies than MSCs grown with similar concentrations of FBS. [13] [14] [15] [16] [17] It is also now possible to obtain commercial sources of human PL to replace FBS. 18 However, because the methods to produce off-the-shelf PL products 19 can vary among manufacturers, it is unclear how different lots of PL, when prepared by different manufacturers, compare with one another. It is also unclear how different industrial-scale lots of PL that are prepared by the same manufacturer compare with one another. The aim of this study was to compare the content and functional activity of multiple lots of serum-based PL (PL-S) that were produced on an industrial-scale basis by the same manufacturer. Using the same good manufacturing practice (GMP)-compliant and standardized method. PL-S was prepared from pooled, expired, platelet-rich plasma (PRP) apheresis units that were collected by US Food and Drug Administration (FDA)-registered blood banks. To manufacture PL-S, PRP apheresis units underwent a freeze/thaw process to obtain plasma-based PL (PL-P). After the conversion of PL-P to PL-S, the units were pooled, mixed, filtered, and dispensed into defined aliquots.
MATERIALS AND METHODS

Industrial-scale manufacturing of PL
Single-donor PRP apheresis units (3 days post-expiration) were obtained from FDA-regulated blood banks and were placed in storage at 2808C. Donors of platelet apheresis units were screened and tested by blood centers for required viral markers (i.e., hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus Types 1 and 2, and syphilis).
Industrial-scale lots of PL-S were manufactured according to our previously published paper. 16 Briefly, frozen PRP units from multiple donors (range, 49-109 units) were thawed at 48C and transferred into satellite bags. Calcium chloride (20% weight/volume) was added, and each bag was stored at 48C. The next day, the bags were centrifuged at 4000 3 g for 20 minutes, and the PL-S was pooled into a large biocontainer (Pall Corporation). Pooled PL-S was filtered using a proprietary process, the final product was aliquoted, and release testing included sterility, biochemical analyses, and a functional assessment. PL-P was produced essentially the same way as PL-S, except that CaCl 2 was not added, and the lot sizes were about one-half the size of the PL-S lots.
Sterility, mycoplasma, and endotoxin testing
Sterility testing was performed on preprocessed pooled PL and on the final product. Preprocessing sterility testing involved an inoculation of BACTEC Plus Aerobic/F, Plus Anaerobic/F, and Myco F/Lytic (Becton Dickinson) culture bottles and then sending the culture bottles to ARUP Laboratories for testing. Final product sterility testing followed US Pharmacopeia <71> guidelines (LABS, Inc.), and mycoplasma testing followed US Pharmacopeia <63> guidelines (Clongen Laboratories). Endotoxin testing was performed using the Endosafe-PTS test system (Charles River).
Biochemical testing
Biochemical tests were sent to ARUP Laboratories. Quantitative sandwich enzyme-linked immunosorbent assays (ELISAs) for platelet-derived growth factor isoform BB (PDGF-BB), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) (all using the Quantikine ELISA Kit; R & D Systems) were performed according to the manufacturer's instructions (R & D Systems).
Functional testing of PL lots
MSCs used for the functional studies were derived from marrow purchased from Lonza Walkersville, Inc. The MSCs were cultured, harvested at Passage 2 (P2), and the single lot of MSCs was aliquoted and stored at 21508C or less until use. Two methods were used to quantitate MSC proliferation responses. The first method used Trypan Blue staining and a manual cell count to quantitate the proliferative response of MSCs. An aliquot of MSCs was thawed, and the cells were seeded at 5000 cells/cm 2 in replicates of three in six-well plates. In parallel, the P2 MSCs were also seeded in T75 flasks at 5000 cells/cm 2 for each condition.
Cells from the T75 flask were used for expansion and subsequent passaging. 
Protein arrays
PL-S (1 mL) from three randomly selected lots was sent to RayBiotec, Inc., for quantitative screening with the Quantibody Human Cytokine Antibody Array 9000. Controls and serial dilutions of cytokine standards were prepared according to the manufacturer's instructions. Array chips were blocked with sample diluent at room temperature. After decanting the diluent from each chip, cytokine standards, controls, and test samples were added to chip wells and were incubated at room temperature for 1 to 2 hours. Each chip was washed three times and then incubated for 1 hour at room temperature in the dark with a cyanine dye (Cy3)-equivalent dye-streptavidin conjugate. The dye was decanted, and chips were washed five times with wash buffer at room temperature, dried, and imaged using a laser scanner equipped with a Cy3 wavelength.
Quantitative data analysis was performed using the Quantibody Q-Analyzer software (RayBiotec, Inc.). Hierarchical clustering of individual protein expression levels was performed to generate heat maps and dendrograms.
Expansion of MSCs for microarrays
MSCs were obtained from the marrow of two different living donors (Lonza) and from a cadaveric donor. Livingdonor marrow was either directly cultured or was first processed using Ficoll gradient-density sedimentation to obtain a mononuclear fraction (MNC) before plating. Organ-donor marrow was obtained as previously described 20 and was subjected to Ficoll gradient-density sedimentation to obtain MNCs, which were stored in frozen aliquots that were thawed and then plated. Whole marrow samples or MNCs were inoculated into T-75 flasks (Corning Costar; Sigma Aldrich) containing basal medium supplemented with 10% FBS, 10% PL-S, or 10% PL-P. In cultures supplemented with PL-P, 2 IU/mL of heparin (APP Pharmaceutical) was added to preclude clot formation. After 48 hours of incubation, nonadherent cells were removed, fresh medium was added, and the medium was changed every 3 to 4 days until cells reached 80 to 90% confluence. The cells were then detached with 0.25% trypsin (HyClone), re-seeded, and expanded for two more passages (P1 and P2). At each passage, cell counts and viabilities were performed. P2 cells were analyzed for MSC cell-surface markers according to International Society for Cellular Therapy guidelines 21 and were frozen in aliquots of 5 3 10 6 MSCs for gene-expression analysis.
Microarray gene-expression analysis
Total RNA was extracted from MSCs using miRNeasy mini kit (Qiagen). RNA quality was evaluated with the Agilent Bioanalyzer 2100 (Agilent Technologies). Test samples and a Universal Human Reference RNA sample (Stratagene) were amplified and labeled by using the Agilent Low Input QuickAmp Labeling Kit; then, the RNA was amplified and subsequently used on 4 3 44-K Whole Human Genome Microarrays (Agilent Technologies). Images of the arrays were acquired using a microarray scanner (G2505B; Agilent Technologies), and image analysis was performed using feature extraction software (version 9.5; Agilent Technologies). The Agilent GE2-v5_95 protocol was applied using default settings. Resulting data files were analyzed using BRB Array Tools developed by the Biometric Research Branch, National Cancer Institute (http:// linus.nci.nih.gov/BRB-ArrayTools.html) and Partek Genomic Suite 6.4 (Partek, Inc.).
Flow cytometry analyses of MSCs
Immunophenotyping of harvested cells was performed using the following fluorescence-conjugated mouse antihuman monoclonal antibodies: CD105-phycoerythrin (CD105-PE), CD45-fluorescein isothiocyanate (CD45-FITC) (both from eBioscience); CD73-PE, CD90-PE-cyanine dye (CD90-PE-Cy5), (CD34-FITC), CD45 peridininchlorophyll proteins (CD45-PerCP), human leukocyte antigen-antigen D related-FITC (HLA-DR-FITC), and CD44-FITC (all from BD Biosciences). Appropriate isotype controls were set up in parallel. At minimum, 20,000 events were collected on a Partec Cyflow flow cytometer (Partec North America, Inc.) using FlowMax software for data acquisition and analysis.
Statistical analysis
Data are presented as mean 6 standard deviation of the mean. A t test was used to determine differences or similarities between populations. All p values less than 0.05 were designated as significant.
RESULTS
Characterization of large-scale PL-S products
From January 2013 to December 2016, nine GMPcompliant, industrial-scale PL-S manufacturing runs (i.e., nine lots) were conducted using a standardized method. The total number of PRP apheresis units per lot production ranged from 48 to 109 units for an average volume of 24.6 6 2.2 liters ( Table 1 ). The amount of time that the PRP units were stored at 2808C before being selected for use in a PL-S manufacturing run was approximately 1 year for Lots 1 through 7 and approximately 3 years for Lots 8 and 9. Postmanufactured average volume recoveries were 18.8 6 2.5 liters for an average total volume recovery of 76 6 5%. In-process sterility testing for all lots was negative, and final product sterility testing revealed that eight lots of PL-S tested negative, and one lot was positive for Propionibacterium, a Gram-positive rod associated with normal human skin flora. Confirmatory testing of the alleged contaminated PL-S lot was inconclusive, suggesting that contamination may have occurred at the time of sterility testing. The eight lots that tested negative for sterility were released, and the one lot that inconclusively tested positive was not released for clinical use. Nine lots of PL-S were tested for biochemical markers. Values for sodium, potassium, chloride, urea nitrogen, and creatinine levels were relatively similar among lots (Fig. 1A,B) . Variations in glucose and calcium levels were noted, with glucose levels averaging 151 mg/ dL (range, 101-230 mg/dL) and calcium levels averaging 70 mg/dL (range, 47-76 mg/dL) (Fig. 1A,B) . Average pH, osmolality, and total protein levels were 6.9 6 0.3, 323 6 10 mOsm/kg, and 5.4 6 0.2 g/dL, respectively (Fig. 1A,B) . Hemoglobin levels averaged 1.5 6 0.7 mg/dL (Fig. 1B) , and fibrinogen levels were below detectable levels (<30 mg/mL; data not shown). Mean growth factor levels were 10.7 6 1.8 ng/mL for PDGF-BB (range, 9.0-14.1 ng/ mL), 0.8 6 0.2 ng/mL for VEGF (range, 0.6-1.0 ng/mL), 3.4 6 0.6 ng/mL for EGF (range, 2.7-4.5 ng/mL), and 0.2 6 0.03 ng/mL for bFGF (range, 0.1-0.2 ng/mL) (Fig. 1C) .
PL support of MSC cultures
Of eight lots tested, PL-S was as good as or better than FBS in expanding MSCs. For six of eight PL-S lots, proliferation responses, doubling times, and growth ratios for MSCs were determined by manual cell counts at P3 and P4. Average MSC fold-expansions at P3 were 7.2 6 2.6 and 3.2 6 0.7, and MSC doubling times were 39.3 6 7.2 hours and 71.5 6 21.0 hours (n 5 6) when cultured with PL-S versus FBS, respectively. Based on fold-expansion, the growth ratios for MSCs cultured in PL-S for Lots 1, 2, 3, 4, 5, and 7 versus FBS (i.e., PL-S/FBS) were determined to be greater than 1.0 for all these lots (Fig. 2, black bars) . This represented an overall average MSC (PL-S/FBS) growth ratio of 2.2 for MSCs at P3. At P4, average fold-expansions with PL-S and FBS were 5.0 6 1.5 and 3.3 6 0.1.1, respectively; and MSC doubling times were 50.8 6 9.2 hours and 76.6 6 24.3 hours (n 5 6), respectively. Based on foldexpansion, this represented an overall average MSC (PL-S/FBS) growth ratio for MSCs of 1.25 at P4.
Given the value of these results, we wanted to develop a less time-consuming functional release assay to test the activity of PL lots that uses an MTT assay. For PL-S Lots 7, 8, and 9, P2 MSCs were thawed and subcultured in 96 well-plates. After 72 hours of culture during MSC P3 formation, a colorimetric measurement of cell proliferation was determined. Using the absorbance measurements, the PL-S/FBS growth ratios were greater than 1.0 (Fig. 2,  white bars) . This represented an overall average MSC (PL-S/FBS) growth ratio of 2.1 for MSCs at P3. Together, these results support the implementation of a functional release test that measures MSC (PL-S/FBS) growth ratios with the MTT assay. 
PL-S is stable up to 2 years at 2808C
The results showed that MSC fold-expansions were greater (Fig. 3A) , and doubling times for MSCs were shorter with PL-S than with FBS when assessed over a 2-year period for each time point tested (Fig. 3B) . The stability of growth factors PDGF-BB, VEGF, EGF, and bFGF in PL-S when maintained at 2808C showed no apparent decreases in growth factor levels over a 2-year storage period. Growth factor levels at time zero for PDGF-BB, VEGF, EGF, and bFGF were 9.9 6 0.6, 0.6 6 0.2, 3.2 6 0.3, and 0.2 6 0.02 ng/mL, respectively; and, after 2 years of storage, growth factor levels were 9.2 6 0.7, 0.7 6 0.1, 2.5 6 0.07, and 0.2 6 0.01 ng/mL, respectively (Fig. 3C ).
Protein array profile
Quantitative measurements of cytokines, growth factors, soluble receptors, and other proteins in three randomly selected PL-S lots revealed that there were similarities as well as dissimilarities among the lots, as is evident by hierarchical cluster profiling (Fig. 4 ). Of 423 cytokines tested, only three were identified as negative (i.e., 0.0 ng/ mL) in all three lots: angiotensin-converting enzyme 2 (ACE-2), tumor necrosis factor (TNF)-related activationinduced cytokine (TRANCE), and single immunoglobulin interleukin-1-related receptor (SIGIRR). Thirty-one proteins were below the limit of detection in all three lots. Three-hundred sixty-seven of the 423 proteins tested (i.e., 87%) were present in all three lots, and 27 of the 423 cytokines were identified in one or two of the three PL-S lots (see Table S1 , available as supporting information in the online version of this paper). Of the 367 proteins that were detected in all three lots, 290 were present with quantitative levels within 50% of one another.
MSC gene expression in response to different protein supplements
Two sets of experiments were conducted to determine how the gene-expression profiles of MSCs would be affected when they were produced in a culture medium that was supplemented with different protein additives. In the first set of experiments, the MSCs used in the experiments were produced in culture from three different sources, which included whole marrow from one living donor, MNCs from a second living donor's marrow, and MNCs from the marrow of an organ donor. Because, at the time of the first gene-profile experiment, our laboratory was still considering whether to manufacture large-scale lots of PL-S or PL-P, both PL-P and PL-S were evaluated relative to FBS. MSC proliferation responses after two passages revealed that similar numbers of MSCs were generated in cultures containing FBS (i.e., 61 6 14 3 10 6 ) and PL-S (i.e., 73.9 6 27 3 10 6 ; p5 0.50), but cultures supplemented with PL-P produced significantly more cells (i.e., 145 6 33 3 10 6 ) than cultures with FBS (p < 0.02) ( Table 2 ). Cultures supplemented with PL-P also outperformed cultures with PL-S (p 5 0.05) ( Table 2) . Independent of the protein supplement that was used in the culture medium, cells expressed markers associated with an MSC phenotype ( Table 3) . Additional comparative data regarding the activities of PL-S, PL-P, and FBS can be found in one of our previous publications. 16 The results of our first gene-expression profile of MSCs revealed that there were fewer differences in geneexpression profiles caused by different medium supplements (i.e., FBS vs. PL-S vs. PL-P) than by the marrow source (Fig. 5) . This was evident from a principal component analysis, which demonstrated that MSCs from Living Donor 1 formed one cluster, a second cluster was observed with Living Donor 2, and a third cluster was observed with the cadaveric marrow (Fig. 5A) . Unsupervised hierarchical culture analysis yielded similar results (Fig. 5A) . A two-way analysis of variance also revealed significant differences among samples caused by the source of the starting cellular material, but not by the different medium supplements. Analysis showed that the differential expression of 22 genes was attributable to differences in starting cellular material (p < 0.05; false discovery rate [FDR] < 0.05) ( Table 4 ). There were far more differentially expressed genes between Living Donor Marrow 1 and cadaveric marrow culture-derived MSCs (i.e., 122 genes) and Living Donor Marrow 2 and cadaveric marrow cultured-derived MSCs (i.e., 543 genes) than for MSCs obtained from Living Donors 1 and 2 (i.e., 15 genes; paired t tests; p < 0.05; FDR < 0.05; data not shown). In contrast, a comparison of differentially expressed genes among the MSCs cultured with FBS versus PL-S and PL-P revealed only two differentially expressed genes (paired t tests; p < 0.05; FDR < 0.05). The two genes were protocadherin a-C2 (PCDHAC2), a neural cadherin-like cell adhesion protein, and A_32_P206104, a CDC42 binding protein kinase b.
In a second experiment, a more direct comparison was performed by culturing MNCs only from living donor marrow. Although significance was not reached, cultures supplemented with PL-S produced more MSCs (i.e., 12.6 6 4.2 3 10 6 ) than with FBS (i.e., 8.0 6 3.0 3 10 6 ), and faster doubling times were noted with PL-S (i.e., 34.9 6 3.8 hr) than with FBS (i.e., 41.6 6 5.3 hr). Cultures were maintained for an average of 17.5 days in medium supplemented with FBS and 16.5 days in medium supplemented with PL-S. Principal component analysis and hierarchical clustering analysis of the global transcriptome data suggested that there were some differences in MSCs caused both by culture media and by intersubject variability (Fig.  5B) . However, a two-way analysis of variance revealed no significant differences in the gene expression of MSCs caused by culture media supplement or marrow source.
DISCUSSION
This is the first study to examine the content and function of PL-S lots that were manufactured with a single, standardized, industrial-scale method. The results demonstrate that, overall, the biochemical properties of different manufactured lots of PL-S are essentially similar, with some slight variations (Fig. 1) . The growth of MSCs cultured with all PL-S lots tested was as good as or better than that of MSCs when grown with FBS. However, there are variations in MSC growth ratios, suggesting that some degree of lot-to-lot variability is present (Fig. 2 ). We also demonstrate that PL-S stored at 2808C is relatively stable over a 2-year storage period.
Platelets contain proteins that play key regulatory roles in cellular growth, cell development, chemotaxis, angiogenesis, and regeneration 22, 23 ; and, when these proteins are released into the supernatant during the manufacturing of PL, they contribute to the quality and potency of the final product. Of 423 different cytokines/ growth factors tested, a large majority (i.e., 87%) are present in all three lots, with only 27 proteins present in one or two of three PL-S lots and only 31 proteins below detection limits in all three lots (see Table S1 ). Of the 367 proteins detected in all three lots, a majority of proteins (i.e., 79%) are present at quantitative levels within 50% of one another. These data indicate that, although there are differences in protein profiles and levels, the majority of proteins are present at similar quantitative levels (i.e., 79%). Moreover, despite lot-to-lot variations in protein levels, the differences do not preclude the ability of PL-S to surpass FBS in supporting MSC growth. A future challenge will be to identify which variations in protein levels are acceptable for the release of PL-S for specific applications. The marrow from one living donor was directly plated into culture medium; the marrow from a second living donor was processed to obtain an MNC fraction, which was then plated; and the marrow from an organ donor (cadaveric) was processed to obtain an MNC fraction that was stored frozen in small aliquots before being plated. Each source of marrow was cultured with aMEM medium supplemented with 10% FBS, 10% PL-P, or 10% PL-S. Principal component analysis of the samples using the entire gene-expression data set is shown in on the left, and unsupervised hierarchical clustering analysis is shown on the right. Results from this study indicate that greater differences in MSC gene-expression profiles are attributable more to different donor marrow sources than to the medium supplement (i.e., PL-S, PL-P, and FBS). The greatest differences in MSC gene expression are observed between living donor marrow and cadaveric marrow, independent of how marrow is processed (i.e., whole blood vs. MNCs). Among differentially expressed genes is HD domain containing 2 (HDDC2) ( Table 4) , a gene that is implicated in maintaining the pluripotency of humaninduced pluripotent stem cells and embryonic stem cells. 24 Also among the 22 genes is CCEBPB, a gene that encodes the transcription factor CCATT/enhancer binding protein (C/EBP), an important adipogenic transcription factor 25 and, when expressed by MSCs, regulates early Bcell lymphopoiesis. 26 Given the differences in MSC gene expression from different marrow sources, these data suggest that there are distinct populations of MSCs residing within specific marrow niches, a notion supported by evidence that MSCs from different tissues of origin are different, such as MSCs from trabecular or cortical marrow. 27 Our results are in contrast to another study, which demonstrated that significant differences in MSC gene expression are present based on whether FBS, human serum, or thrombin-activated platelet releasate plasma is used. 28 It is worth noting that several factors are different between these two studies. A major motivating factor for replacing FBS with human PL in cell cultures is to avoid the risks associated with transmitting infectious bovine agents (i.e., parvovirus and prions) and to eliminate any exposure to residual xenoproteins that have the potential to cause an immune reaction in recipients. There is no question that exposures to zoonotic diseases and residual xenoproteins are eliminated when using human PL. However, because PL is derived from human blood products (i.e., PRP), there is still a potential for transmitting human viruses (e.g., hepatitis B, hepatitis C, human immunodeficiency virus), for transferring bacterial agents, and for exposing someone to allogeneic proteins that may cause an immune reaction. Currently, PL has not yet been implicated in any such transmissions or exposures. This may be due in part to the fact that the use of PL as a culture supplement is a relatively new practice. Also, it may be attributable to safety measures for blood products that have been put in place by the transfusion community to minimize viral transmissions associated with blood transfusions. For example, the implementation of nucleic acid testing for the detection of viral diseases has greatly improved the safety of blood products 29 along with the more recent adoption by some blood centers of pathogen-reduction for platelet products to eliminate viral and bacterial contamination, a practice that someday may translate into safer PL products. 30, 31 Sterile filtration of a PL final product and sterility testing are also strategies to minimize potential bacterial transmissions. In addition, a practice that may minimize exposure to allogeneic proteins is the exercise of washing the harvested cell suspension prior to adding an injectable solution (e.g., Plasmalyte A) to prepare the cells for a clinical application, a practice that has been noted to reduce the presence of a serum supplement by several-logs.
Whether washing the cell suspension before it is infused The differentially expressed genes were identified with two-way analyses of variance using p < 0.05 and an FDR < 0.05.
into a patient successfully eliminates the possibility of any immune reactions attributable to allogenic proteins remains an open question.
Comparative analyses of large-scale lots of PL-S demonstrate that there are similarities as well as variations in the protein profiles of different PL-S lots. However, despite differences in protein profiles, all PL-S lots outperform FBS and are effective substitutes for FBS in supporting MSC expansion. We propose that a standardized, functional, minimum criterion be established to release PL, stating that MSC expansion at a specific concentration of PL is equal to or greater than MSC expansion with 10% FBS (i.e., MSC growth ratio 1.0). Such a specification would allow for some of the inherent variability among different PL compositions and, at the same time, help to define acceptable tolerance limits for cytokines and other active ingredients that are needed to achieve a specific response for a specific application (i.e., MSC vs lymphocyte cultures).
